Articles

With all due speed

Agilent prepares to acquire Velocity 11 in an effort to offer more complete workflows
Written byJeffrey Bouley
| 3 min read

SANTA CLARA, Calif.-Though they may differ vastly in size and reach, Agilent Technologies Inc. and Velocity11 share a similar core design philosophy and core business ethics, which is one of the reasons the two companies are working to finalize an acquisition deal that would bring the privately held automated liquid handling and laboratory robotics company into the Agilent fold.

It also doesn't hurt that Velocity11 has been recognized as one of the fastest-growing companies not just in Silicon Valley but also in North America, notes Nick Roelofs, vice president and general manager of the Agilent Life Sciences Solutions Unit.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Illustration of an antibody intertwined with a DNA double helix.
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.